Evidence map›Paper›PMID 41811229›Full record

ArticleHLA2026

Landscapes of HLA Mismatching in Contemporary Unrelated Haematopoietic Cell Transplantation.

Esteban Arrieta-Bolaños, Edouard F Bonneville, Pietro Crivello, Tobias Gedde-Dahl, Régis Peffault de Latour, Urpu Salmenniemi, Nicolaus Kröger, Ibrahim Yakoub-Agha, Marco Zecca, Goda Choi and 12 more

Abstract read
In one paragraph

Article in HLA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Esteban Arrieta-BolañosInstitute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany.ORCID https://orcid.org/0000-0002-3696-5803
Edouard F BonnevilleDepartment of Biomedical Data Sciences, LUMC, Leiden, the Netherlands.ORCID https://orcid.org/0000-0001-7542-4498
Pietro CrivelloInstitute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany.ORCID https://orcid.org/0000-0001-9668-5013
Tobias Gedde-DahlOslo University Hospital, Rikshospitalet, Oslo, Norway.
Régis Peffault de LatourSaint-Louis Hospital, BMT Unit, Paris, France.
Urpu SalmenniemiHUCH Comprehensive Cancer Center, Helsinki, Finland.
Nicolaus KrögerUniversity Medical Center Hamburg, Hamburg, Germany.
Ibrahim Yakoub-AghaCHU de Lille, Univ Lille, INSERM U1286, Lille, France.
Marco ZeccaSan Matteo Pavia Transplant Programme, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.ORCID https://orcid.org/0000-0002-8818-1744
Goda ChoiUniversity Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Charles CrawleyAddenbrookes Hospital Cambridge, Cambridge, UK.
Eleni TholouliManchester Royal Infirmary, Manchester, UK.
Valérie DuboisHistocompatibility Laboratory, EFS Lyon, Lyon, France.
Juha PeräsaariClinical Laboratory Services, Histocompatibility Testing, Finnish Red Cross Blood Service, Vantaa, Finland.ORCID https://orcid.org/0000-0002-1142-3792
Lotte WietenTransplantation Immunology, Maastricht University Medical Center, Maastricht, the Netherlands.
Steven G E MarshUCL Cancer Institute, London, UK.ORCID https://orcid.org/0000-0003-2855-4120
Mats BengtssonDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.ORCID https://orcid.org/0000-0003-2612-0724
Jorinde D HoogenboomEBMT Leiden Study Unit, Leiden, the Netherlands.
Jürgen KuballDepartment of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands.
Florent MalardSorbonne Université, Centre de Recherche Saint-Antoine (CRSA) INSERM UMRs938, Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine AP-HP, Paris, France.
Annalisa RuggeriSan Raffaele Scientific Institute, Hematology and Bone Marrow Transplantation Unit, Milan, Italy.
Katharina FleischhauerInstitute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany.

Funding

Deutsche Knochenmarkspenderdatei DKMS-SLS-JHRG-2021-02Dr. Werner Jackstädt-StiftungJosé Carreras Leukämie-Stiftung DJCLS 17R/2023Joseph Senker Stiftung
6 · The paper itself

Abstract

Haematopoietic cell transplantation (HCT) with HLA-mismatched unrelated donors (MMUD) offers access to curative therapy for patients lacking well-matched donors. Accumulating evidence suggests that functional matching among allele-mismatched pairs can significantly influence patient outcomes. Therefore, real-world data on mismatch frequencies in MMUD-HCT could provide fundamental information for the assessment of patient risks and donor selection strategies. Here, we analysed HLA matching in 28,376 first unrelated transplants reported to the EBMT Registry with available 6-locus high-resolution typing. Mismatches at each locus were quantified and characterised at the allelic, antigenic and functional (antigen-recognition domain, peptide-binding motif) levels. 25% of the transplants were performed across one (9/10; n = 6053) or more (< 9/10; n = 1013) high-resolution mismatches at the five main HLA loci, a proportion that was markedly higher (43.9%) among transplants performed with post-transplantation cyclophosphamide (PTCy). Median time from diagnosis to transplant was longer for MMUD compared to 10/10 transplants, but this difference decreased over time (14.9 vs. 11.3 months pre-2011, p = 0.003; 8.1 vs. 7.4 months 2021-2022, p = 0.016). Across transplant eras, single class I mismatches were three times more common than class II mismatches. Conversely, matching for HLA-DPB1 increased from 15% pre-2011 to 31% in 2021-2022. The landscapes of allelic mismatches differed markedly between HLA loci. For class II, skewed distributions dominated by frequent combinations result in significantly higher frequencies of functional matching compared to class I in both PTCy and non-PTCy pairs. Our study constitutes the first large-scale characterisation of real-world HLA mismatch frequencies in contemporary unrelated HCT, bearing implications for future clinical outcome studies.

Indexed as

Hematopoietic Stem Cell TransplantationHistocompatibilityHistocompatibility TestingHLA AntigensUnrelated DonorsAdolescentAdultAllelesChildChild, PreschoolCyclophosphamideFemaleGraft vs Host DiseaseHumansInfantMaleCyclophosphamideHLA Antigensalloreactivityfunctional matchinghistocompatibilityHLAimmunopeptidomemismatches

Identifiers

PMID41811229
PMCPMC12978212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.